TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Stock Information for Kintara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kintara Therapeutics Inc.

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates NVEI, CHX, KTRA, ABIO
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - KTRA, CHX, NVEI, ADTH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, KTRA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.